Pathstone Holdings
NRSN icon

Pathstone Holdings’s NeuroSense Therapeutics NRSN Stock Holding History

Pathstone Holdings’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5K Hold
16,528
– – ﹤0.01% 2213
2025
Q4 		$12.7K Buy
+16,528
New +$17.4K ﹤0.01% 2215

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Pathstone Holdings's NRSN Position: Q1 2026 in Review

Pathstone Holdings held its NeuroSense Therapeutics (NRSN) position steady in Q1 2026 at 16,528 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2213.

Pathstone Holdings first reported a position in NRSN in Q4 2025 and has held it in 2 quarters since. The position peaked at $12.7K in Q4 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • Pathstone Holdings held 16,528 shares of NeuroSense Therapeutics worth $12.5K as of Q1 2026.
  • Pathstone Holdings left its NeuroSense Therapeutics share count unchanged in Q1 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q1 2026, its #2213 holding.
  • Pathstone Holdings first reported a position in NeuroSense Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pathstone Holdings's NeuroSense Therapeutics position peaked at $12.7K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.